Результаты поиска

[The mitochondrial organelle and the heart].

The heart is highly dependent for its function on oxidative energy generated in mitochondria, primarily by fatty acid beta-oxidation, respiratory electron chain and oxidative phosphorylation. Defects in mitochondrial structure and function have been found in association with cardiovascular diseases such as dilated and hypertrophy cardiomyopathy, cardiac conduction defects and sudden death, ischemic and alcoholic cardiomyopathy, as well as myocarditis. While a subset of these mitochondrial abnormalities have a defined genetic basis (e.g. mitochondrial DNA changes leading to oxidative phosphoryl

Sudden death due to metronidazole/ethanol interaction.

Metronidazole (Flagyl), a commonly prescribed antimicrobial agent, can produce a reaction similar to that of disulfiram (Antabuse) when administered to patients drinking ethanol. This drug/chemical interaction results in accumulation of acetaldehyde in the blood. Acetaldehyde is hepatotoxic, cardiotoxic, and arrythmogenic; no lethal serum acetaldehyde level has been established. Sudden death has been reported in patients taking disulfiram while using ethanol; no fatalities have been reported due to ethanol/ metronidazole interactions. Described is a case of a 31-year-old woman who died moments

[Use of dobutrex in critical states in patients with acute poisoning of chemical etiology].

Efficacy of dobutrex was assessed in 75 patients with grave poisonings. In 45 of these poisoning with cardiotoxic agents was complicated by acute heart failure and in 30 poisoning with psychopharmacological agents involved secondary disorders of cardiac contractile function. A sharp reduction of cardiac contractile function and output were observed in all the cases. Treatment efficacy was assessed by monitoring the parameters of central hemodynamics and by phase analysis of left-ventricular systole by rheopolycardiography with recording by mingograf-82. The results indicated a rapid and effect

Daunorubicin. Results in childhood leukaemia.

Fifty children with acute leukaemia (44 lymphatic, 6 myeloid) were treated with daunorubicin. In 3 cases, it was given in courses of daily i … side-effect was bone marrow depression with the related complications of haemorrhage and infection. Cardiotoxicity was not a problem; the cumulative total dose of daunorubicin did not exceed 26·8 mg/kg. This study indicates that intermittent dosage with 2-3 mg/kg at intervals of 7 to 14 days is as effective as, and no more toxic than, the courses of daily inject …

Cardiovascular Symptom Tracking Among Patients With Cancer in Cardio-Oncology Care: Qualitative Study Using the Capability, Opportunity, Motivation-Behavior (COM-B) Framework.

BACKGROUND: Cardiovascular disease is a leading noncancer cause of morbidity and mortality among individuals diagnosed with cancer. Although modern cancer therapies have improved survival, many are associated with cardiotoxic effects that increase the risk of cardiovascular complications. Early identification of cardiovascular symptoms and signs may support timely clinical management. However, tracking cardiovascular health during cancer care can be complex for both patients and medical team participants, and important indicators, such as blood pressure changes, heart rate variability, fluid r

Совпадение в полном тексте источника
… Patients described varying levels of awareness of cardiotoxicity risks and challenges with real-time documentation, while medical team participants noted difficulty attributing symptoms specifically to cardiotoxicity. … As one medical team participant stated: They’re not always related to cardiotoxicity, it could just be coincidental…but then, other times, it’s clearly due to their cardiotoxicity of their cancer therapy. …

Long-Term Fatigue After Treatment for Breast Cancer.

IMPORTANCE: Patients with breast cancer (BC) may have long-term fatigue after treatment, which is associated with reduced quality of life. OBJECTIVE: To identify cardiac, psychological, and cancer treatment factors associated with fatigue before and 24 months after BC treatment. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted across multiple community hospital-based cancer centers among participants with stage I to III BC receiving potentially cardiotoxic chemotherapy or aromatase inhibitors and noncancer comparators. Participants were enrolled from May 2017 to July 2021 a

Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system.

Introduction: With the widespread application of Immune checkpoint inhibitors (ICIs), it is important to explore the association between ICI … tion regimen. Moreover, reports of ICI-associated arrhythmias were associated with other concurrent cardiotoxicity, including cardiac failure [ROR 2.61 (2.20-3.09)], coronary artery disorders [ROR 2.28 (1.83-2.85)], myocardial disorders [ROR 5.25 (4.44-6.22)], pericardial disorders [ROR 2.76 (2.09-3.64)] and cardiac valve disorders [ROR 3.21 (1.34-7.68)]. Conclu …

The efficacy and cardiac toxicity of different-dose pegylated liposomal doxorubicin in elderly patients with diffuse large B lymphoma.

OBJECTIVES: In order to explore the impact of pegylated liposomal doxorubicin (PLD) dose intensity on survival outcomes of newly diagnosed e … nd RCdOP (58 cases) (PLD 30-45 mg/m2 ). The effects of different doses of PLD on clinical efficacy, cardiotoxicity and prognosis of patients were retrospectively analyzed. Subgroup analysis was performed to compare the clinical characteristics of different subgroups. RESULTS: Our study showed that PLD and epirubicin had similar efficacy (overall survival (OS) p …

A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.

Based on preclinical data, we designed a phase I/II clinical trial to determine the efficacy and toxicity of doxorubicin followed by paclita … utropenia (< 500/microL) in 20% of cycles with no significant clinical events. No relevant clinical cardiotoxicity was observed. Other toxicities included mild peripheral neuropathy and mild myalgia/arthralgia (In 37.5% and 30.4% of cycles, respectively). The maximum tolerated paclitaxel dose was not reached at the 250 mg/m2 dose level. In the second phase, 13 p …

Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitors: Interpreting the Discrepancy Between Clinical Trials and Real-World Data.

Real-world data on cardiovascular immune-related adverse events (CV-irAEs) in cancer patients treated with immune checkpoint inhibitors (ICI … iencing CV complications associated with ICIs. Longer follow-up period and different definitions of cardiotoxicity may account for the higher cardiotoxicity rates that seem to reflect an emerging threat.

[Effects of new antineoplastic agents (dimethoxybenflurone and Oracin) on the cardiovascular system and other parameters in the rabbit in vivo].

Anthracycline derivatives belong among the most effective antineoplastic drugs but their therapeutic use is limited by their side effects--a dose-related cardiotoxicity. The influence of repeated i.v. administration (once weekly, max. 10 weeks) of new antineoplastic agents--dimethoxybenfluron (DMB) (3,9-dimethoxybenfluron hydrochloride, C23H24O4NCl, M.w. 413.9, Institute of Experimental Biopharmaceutics, Czech Academy of Sciences, Hradec Králové, Czech Republic; 12 or 24 mg base/kg) and Oracin (6-[2-(2-hydroxyethyl)aminoethyl]-5,11-dioxo-5,6-dihydro-11H- indeno[1,2c]isoquinoline hydrochloride)…

Humanized hiPSC Platforms for I/R Injury: Advancing Toward Precision Cardioprotection.

Myocardial ischemia-reperfusion (I/R) injury remains a major contributor to infarct expansion, adverse remodeling, and heart failure despite … ths and limitations of current platforms, and discuss their use in mechanism-guided drug screening, cardiotoxicity assessment, and patient-specific preclinical modeling. We emphasize that these systems are not yet substitutes for clinical validation or whole-organ physiology. Their current value lies in providing controllable, human-relevant preclinical models t …

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy.

BACKGROUND/OBJECTIVES: Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but c … ologists is recommended for comprehensive care. Identifying hematological biomarkers for predicting cardiotoxicity and exploring cardioprotective therapies for high-risk patients should be prioritized. CONCLUSIONS: It is essential to educate healthcare providers about the CV risks associated with BTKis. Additionally, clinical guidelines should be regularly upda …

Blood pressure variability as predictor of cancer therapy-related cardiovascular toxicity in patients with Multiple Myeloma.

Blood pressure (BP) variability (BPV) is an independent predictor of cardiovascular (CV) events. The role of BPV in defining risk of cancer therapy-related cardiovascular toxicity (CTR-CVT) is currently unknown. The aims of this study were: (i) to evaluate BPV in a population of patients with Multiple Myeloma, undergoing proteasome inhibitors therapy; (ii) to assess the predictive value of BPV for CTR-CVT; (iii) to analyze clusters of subjects based on BPV. One hundred twenty-four patients underwent a baseline evaluation, including Ambulatory Blood Pressure Monitoring (ABPM), PWV, and Echocard

[The Cardio-Oncology Guideline - A Comprehensive Approach to Managing Cardiovascular Risks in Cancer Patients].

The emerging field of cardio-oncology addresses the critical need for specialized cardiovascular care in cancer patients, given the overlapp … d myocarditis (ICIM), as well as the role of statins in protecting against anthracycline-associated cardiotoxicity.

The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer.

BACKGROUND: The 2022 ESC Guidelines on Cardio-Oncology recommend baseline cardiovascular risk stratification before starting anticancer drug … 37 medium, 9 high, 2 very-high risk criteria. We found a significantly higher incidence of overall cardiotoxicity (CTRCD and other cardiovascular events) in the very-high risk group (100%) compared with the medium (29%) and low risk groups (13%). CTRCD incidence was also significantly higher in the high risk group (55%). CTRCD resulted as being associated with …

Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.

PURPOSE OF REVIEW: Patients with cancer have an elevated risk of cardiovascular disease. This review describes the cardiovascular risks of d … cally for radiation-related heart and vascular disease, immunotherapy myocarditis, fluoropyrimidine cardiotoxicity, vascular endothelial growth factor inhibitor-related hypertension, BCR-Abl multikinase inhibitor vascular disease, and other established and emerging cancer therapeutics with cardiovascular effects. Current evidence supports specific cardioprotecti …

Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials.

INTRODUCTION: Many concerns still exist regarding the safety of hydroxychloroquine (HCQ) in the treatment of Coronavirus Disease 2019 (COVID-19). OBJECTIVES: The purpose of this study was to evaluate the safety of HCQ in the treatment of COVID-19 and other diseases by performing a systematic review and meta-analysis. METHODS: Randomized controlled trials (RCTs) reporting the safety of HCQ in PubMed, Embase, and Cochrane Library were retrieved starting from the establishment of the database till June 5, 2020. Literature screening, data extraction, and assessment of risk bias were performed in

Evaluation of the Effectiveness of Sugammadex for Digoxin Intoxication: An Experimental Study.

Previous studies have shown that cyclodextrin group medicines bind to various drugs. The hypothesis of our study is to determine whether sug … gher than control group (p < 0.05). We found that the 1000 mg/kg dose of sugammadex delayed digoxin cardiotoxicity in a rat model of digoxin toxicity. We conclude that further research must be conducted on the interaction between digoxin and sugammadex.